Now Reading: AIDAN welcomes NPPA margin cap but demands manufacturer price control
-
01
AIDAN welcomes NPPA margin cap but demands manufacturer price control
The Story in Brief
The All India Drug Action Network (AIDAN) has welcomed the National Pharmaceutical Pricing Authority’s (NPPA) 30% cap on trade margins for 137 non-scheduled anti-cancer drugs, but called it a half-baked price control that leaves manufacturer pricing untouched. AIDAN member Dr Anant Phadke said wholesale and retail dealers have earned average margins of 170%, with some reaching 700%, and that about 204 of 900 affected medicines will see no reduction or only up to 10%. The group demanded cost-based price regulation extended to all anti-cancer medicines, compulsory licensing of patented drugs under the Indian Patents Act, and adoption of the Janaushadhi generic medicine model.
The NPPA action, following Supreme Court directives, reduces maximum retail prices by up to 93% on some formulations, but excludes costly originator brands, patented medicines and brand premiums. In a separate discussion at The Hindu, former Ayushman Bharat CEO Indu Bhushan and legal adviser K.M. Gopakumar debated whether lower MRPs translate into affordable care, suggesting price regulation alone may not ensure comprehensive access. BusinessLine, in an editorial, cautioned that pricing interventions must preserve medicine quality and future investment incentives.
Update, 6 November 2026: BusinessLine (5 November) editorialises the NPPA margin cap, emphasising that price cuts must be assessed through actual savings for patients and balanced against supply and innovation incentives. It cites the 2019 trade-margin rationalisation as a precedent. The editorial adds a supply-chain perspective absent from AIDAN’s demands, arguing that distribution costs should not automatically be treated as manufacturer profits.
Indian Opinion Analysis
AIDAN’s press statements, reported by The Times of India, dominate the coverage with specific demand language, cost-plus pricing from the Janaushadhi model and compulsory licensing. The Hindu frames the development as a policy debate through a moderated discussion transcript, foregrounding the limitations of price regulation alone. BusinessLine offers an editorial perspective that supports price controls but warns about preserving supply and investment incentives. The common thread across all sources is acceptance of the NPPA margin cap as necessary but incomplete, the difference lies in whether the primary critique is manufacturer profiteering or structural gaps in affordability. AIDAN’s specific figures (204 medicines with no or minimal reduction) appear only in The Times of India, while supply-chain concerns addressed by BusinessLine are absent from AIDAN’s demands. The conversation transcript in The Hindu leaves open the question of how lower MRPs translate into patient-level affordability, a question none of the three sources resolves.
Coverage: 3 sources, 3 neutral
Sources (3): timesofindia.indiatimes.com (neutral report), thehindu.com (neutral report), thehindubusinessline.com (neutral report)
This brief was synthesised by AI from the 3 sources linked above, so one read covers every framing they carry. Methodology and corrections.
